<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00803088</url>
  </required_header>
  <id_info>
    <org_study_id>08-01</org_study_id>
    <nct_id>NCT00803088</nct_id>
  </id_info>
  <brief_title>Safety of Bronchial Thermoplasty Performed With the Alair® System During Two Treatment Sessions to Treat Severe Asthma</brief_title>
  <acronym>3to2</acronym>
  <official_title>A Multicenter Clinical Trial Evaluating the Safety of Bronchial Thermoplasty Performed With the Alair® System During Two Treatment Sessions to Treat Severe Asthma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this multicenter, single-arm, open-label clinical study is to evaluate the&#xD;
      safety of performing bronchial thermoplasty with the Alair® System during two treatment&#xD;
      sessions to treat severe asthma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Current treatment regimen of 3 procedures considered acceptable.&#xD;
  </why_stopped>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Event Profile</measure>
    <time_frame>3 Months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment of airways with the Alair System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>The Alair System</intervention_name>
    <description>Treatment of airways with the Alair System</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject is an adult between the ages of 18 to 70 years.&#xD;
&#xD;
          -  Subject is able to read, understand, and sign a written Informed Consent form to&#xD;
             participate in the Study.&#xD;
&#xD;
          -  Subject has asthma and is taking maintenance asthma medication that includes:&#xD;
&#xD;
               1. Inhaled corticosteroid (ICS) at a dosage ≥1000μg beclomethasone per day or&#xD;
                  equivalent, AND long acting β2-agonist (LABA) at a dosage of ≥100μg per day&#xD;
                  Salmeterol or equivalent.&#xD;
&#xD;
               2. Other asthma medications such as leukotriene modifiers, or anti-IgE, are&#xD;
                  acceptable (Subjects on Xolair® must have been on Xolair for greater than 1&#xD;
                  year).&#xD;
&#xD;
               3. Oral corticosteroids (OCS) at a dosage up to, but not greater than, 10mg per day.&#xD;
&#xD;
          -  Subject has an AQLQ score at Baseline of 6.25 or less.&#xD;
&#xD;
          -  Subject has a Pre-bronchodilator FEV1 of greater than or equal to 60% of predicted&#xD;
             after medication stabilization during the Baseline Period.&#xD;
&#xD;
          -  Subject has a PC20 &lt; 8mg/ml per methacholine inhalation test using standardized&#xD;
             methods*.&#xD;
&#xD;
          -  Subject has at least one day of asthma symptoms during the 2 weeks of the Baseline&#xD;
             Diary Period.&#xD;
&#xD;
          -  Subject is a non-smoker for 1 year or greater (if former smoker, less than 10 pack&#xD;
             years total smoking history).&#xD;
&#xD;
          -  Subject is able to undergo bronchoscopy in the opinion of the Investigator or per&#xD;
             hospital guidelines.&#xD;
&#xD;
          -  Subject is willing and able to comply with the Study protocol, attending follow-up&#xD;
             visits, and requirements for taking and abstaining from medications.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject participated in another clinical trial within 6 weeks of the Baseline Period&#xD;
             involving respiratory intervention that could affect the outcome measures of this&#xD;
             Study.&#xD;
&#xD;
          -  Subject requirement during the Baseline Diary period for rescue medication use other&#xD;
             than for prophylactic use for exercise exceeds an average of:&#xD;
&#xD;
               1. 8 puffs per day of short-acting bronchodilator, or&#xD;
&#xD;
               2. 4 puffs per day of long-acting rescue bronchodilator, or&#xD;
&#xD;
               3. 2 nebulizer treatments per day.&#xD;
&#xD;
          -  Subject has a post-bronchodilator FEV1 of less than 65% of predicted.&#xD;
&#xD;
          -  Subject had three or more hospitalizations for exacerbations of asthma in the prior 12&#xD;
             months.&#xD;
&#xD;
          -  Subject has a recent history of life-threatening asthma, defined by at least one&#xD;
             intubation for asthma within the past five years.&#xD;
&#xD;
          -  Subject had an ICU admission for asthma within the prior 24 months.&#xD;
&#xD;
          -  Subject had four or more infections of the lower respiratory tract requiring&#xD;
             antibiotics in the prior 12 months.&#xD;
&#xD;
          -  Subject had four or more asthma exacerbations requiring oral steroid pulses in the&#xD;
             prior 12 months.&#xD;
&#xD;
          -  Subject has a known sensitivity to medications required to perform bronchoscopy (such&#xD;
             as lidocaine, atropine, benzodiazepines, or other parasympathomimetic agents).&#xD;
&#xD;
          -  Subject is undergoing immunosuppressant therapy other than steroids (e.g.,&#xD;
             methotrexate).&#xD;
&#xD;
          -  Subject uses systemic beta-adrenergic blocking agents.&#xD;
&#xD;
          -  Subject is an insulin-dependent diabetic.&#xD;
&#xD;
          -  Subject is pregnant or a nursing mother, or has plans to become pregnant within the&#xD;
             next 12 months.&#xD;
&#xD;
          -  Subject has other respiratory diseases including interstitial lung disease, emphysema,&#xD;
             cystic fibrosis, vocal cord dysfunction, mechanical upper airway obstruction,&#xD;
             Churg-Strauss syndrome, or active allergic bronchopulmonary aspergillosis (current&#xD;
             total IgE of &gt;1000 Units/mL with positive specific IgE to aspergillus and evidence of&#xD;
             central bronchiectasis).&#xD;
&#xD;
          -  Subject has significant segmental atelectasis, lobar consolidation, significant or&#xD;
             unstable pulmonary infiltrate, or pneumothorax, confirmed on X-ray.&#xD;
&#xD;
          -  Subject has chronic sinus disease as defined by five or more episodes of sinusitis in&#xD;
             past 12 months, or continuous symptoms of sinus infection (purulent discharge) and&#xD;
             significant change in nasal steroid dosage in last six weeks.&#xD;
&#xD;
          -  Subject has uncontrolled sleep apnea (sleep apnea not controlled by either dental&#xD;
             appliances or continuous airway positive pressure (CPAP)).&#xD;
&#xD;
          -  Subject has uncontrolled gastro-esophageal reflux disease as defined by a significant&#xD;
             increase in therapy in last six weeks.&#xD;
&#xD;
          -  Subject has lung cancer or a history of lung cancer.&#xD;
&#xD;
          -  Subject currently has active cancer or a history of cancer with less than 5 years&#xD;
             disease free survival time (whether or not there is evidence of local recurrence or&#xD;
             metastases). Localized basal cell carcinoma (without metastases) of the skin is&#xD;
             acceptable.&#xD;
&#xD;
        (Subject with a history of cancer (excluding lung cancer) and a five year or more disease&#xD;
        free survival time may only be included in this Study by agreement of Sponsor on a case by&#xD;
        case basis).&#xD;
&#xD;
          -  Subject has a history of epilepsy.&#xD;
&#xD;
          -  Subject currently has clinically significant cardiovascular or neurovascular disease,&#xD;
             including myocardial infarction with congestive heart failure, angina, clinically&#xD;
             significant cardiac dysrhythmia or conduction defect, cardiomegaly, cardiomyopathy,&#xD;
             aortic aneurysm, cerebral vascular disease, or stroke.&#xD;
&#xD;
          -  Subject is on anticoagulant therapy, has a bleeding diathesis, platelet dysfunction,&#xD;
             or thrombocytopenia with platelet count less than 125,000/mm2 or known coagulopathy&#xD;
             (INR &gt; 1.5).&#xD;
&#xD;
          -  Subject has uncontrolled hypertension (&gt;200mm Hg systolic or &gt;100mm Hg diastolic&#xD;
             pressure).&#xD;
&#xD;
          -  Subject has an electrical stimulation device such as a pacemaker, defibrillator, or&#xD;
             deep nerve or deep brain stimulator.&#xD;
&#xD;
          -  Subject has a psychiatric disorder that in the judgment of the Investigator could&#xD;
             interfere with provision of Informed Consent, completion of tests, therapy, or&#xD;
             follow-up visits.&#xD;
&#xD;
          -  Subject has any other medical condition that in the Investigator's opinion would make&#xD;
             them inappropriate for Study participation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>December 4, 2008</study_first_submitted>
  <study_first_submitted_qc>December 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2008</study_first_posted>
  <last_update_submitted>January 27, 2021</last_update_submitted>
  <last_update_submitted_qc>January 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>This study was cancelled prior to initiation.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

